Results 91 to 100 of about 481,852 (106)

Amiodarone Therapy: Updated Practical Insights. [PDF]

J Clin Med
Șorodoc V, Indrei L, Dobroghii C, Asaftei A, Ceasovschih A, Constantin M, Lionte C, Morărașu BC, Diaconu AD, Șorodoc L.   +9 more
europepmc   +1 more source

A Polar Radical Pair Pathway To Assemble the Pyrimidinone Core of the HIV Integrase Inhibitor Raltegravir Potassium

Angewandte Chemie, 2008
The UN and WHO currently estimate that 40 million people are living with HIV/AIDS worldwide. Combination therapies using reverse transcriptase and protease inhibitors have been highly successful, but the emergence of drug resistance prompts a search for ...
Philip J. Pye, David Askin, Robert A. Reamer, Kendall N. Houk, Yong-Li Zhong, Gavin O. Jones   +5 more
semanticscholar   +6 more sources

A Facile Synthesis of Raltegravir Potassium—An HIV Integrase Inhibitor

Journal of Heterocyclic Chemistry, 2019
A facile, cost‐effective, and commercially viable synthesis of Raltegravir Potassium (1) has been developed from 2‐(1‐amino‐1‐methyl‐ethyl)‐N‐[(4‐fluorophenyl)methyl]‐1,6‐dihydro‐5‐hydroxy‐1‐methyl‐6‐oxo‐4‐pyrimidinecarboxamide (9) with high purity and in good yields.
Kishore Karumanchi, Gangadhara Bhima Shankar Nangi, Subba Reddy Danda, Ramadas Chavakula, Raghu Babu Korupolu, Kishore Babu Bonige   +5 more
semanticscholar   +4 more sources

Crystal structure of raltegravir potassium, C₂₀H₂₀FKN₆O₅

Powder Diffraction, 2015
The crystal structure of the potassium salt of raltegravir has been solved and refined using synchrotron X-ray powder diffraction data, and optimized using density functional techniques. Raltegravir potassium crystallizes in space groupP21/c(#14) witha= 15.610 59(9),b= 8.148 19(3),c= 16.125 97(6) Å,β= 94.1848(5)°,V= 2045.72(1) Å3, andZ= 4.
James A. Kaduk, Amy M. Gindhart, Kai Zhong, Thomas N. Blanton   +3 more
semanticscholar   +4 more sources

Biowaiver monograph for immediate-release solid oral dosage forms: Raltegravir potassium

Journal of Pharmaceutical Sciences
The present monograph discusses the possibility of BCS-based biowaivers for immediate release pharmaceutical products containing raltegravir potassium, which is used to treat human immunodeficiency virus (HIV) infections. Raltegravir potassium can be assigned to BCS class II or IV since this compound has low solubility and uncertain permeability ...
Atsushi Kambayashi, Masaki Iida, Makoto Ishihara, Yoshinori Takahashi, Bertil Abrahamsson, Naseem A. Charoo, Rodrigo Cristofoletti, Peter Langguth, Mehul Mehta, Alan Parr, James E. Polli, Vinod P. Shah, Jennifer Dressman   +12 more
semanticscholar   +4 more sources

Synthesis of the HIV Integrase Inhibitor Raltegravir Potassium

Synfacts, 2011
Enantioselective Total Syntheses of Three Cladiellins (Eunicellins): A General Approach to the Entire Family of Natural ...
Y.-L. Zhong, P. J. Pye, G. R. Humphrey
semanticscholar   +4 more sources

Raltegravir Potassium

, 2021
openaire   +2 more sources

Raltegravir Potassium – Rufinamide

, 2018
openaire   +2 more sources

Raltegravir Potassium

, 2010

openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Maximizing and stabilizing luminescence from halide perovskites with potassium passivation

Nature, 2018
M. Abdi‐Jalebi, Zahra Andaji‐Garmaroudi, Stefania Cacovich, C. Stavrakas, Bertrand Philippe, Johannes M. Richter, Mejd Alsari, Edward P. Booker, E. Hutter, Andrew J Pearson, Samuele Lilliu, T. Savenije, H. Rensmo, G. Divitini, C. Ducati, R. Friend, S. Stranks   +16 more
semanticscholar   +1 more source